Post-finasteride syndrome: what is and is not known

Post-finasteride syndrome is the name given to sexual, physical and neuropsychiatric symptoms that people report continuing after they stop taking finasteride. It is the reason this drug is argued about at all, and it is the hardest thing on this site to write honestly, because the two easy positions — that it is proven, and that it is imaginary — are both unsupported by the documents.

What follows is organised by who said it and when. That is a slower read than a verdict, and it is the only defensible way to handle a question where the regulators themselves are careful.

Where the name comes from

The name is not a regulator's coinage. The earliest official use we could find and read is a March 2016 bulletin from Medsafe, New Zealand's medicines authority, published in its Prescriber Update. It is headed "Post-Finasteride Syndrome", it says the symptoms often persist after the patient has stopped taking finasteride, and it tells prescribers to discuss them before treatment starts.

Two things about that article should be said in the same breath as its title. Medsafe flags on the page that it is more than five years old and some content may no longer be current. And its table of symptoms — which runs from loss of libido and erectile dysfunction through muscle weakness, cognitive impairment and depression to completed suicide — is referenced to the Post-Finasteride Syndrome Foundation, a patient advocacy organisation, not to a trial. Medsafe also cites a US National Institutes of Health rare-disease entry from 2015 titled "Adverse events of 5-alpha-reductase inhibitors". We tried to open that entry at its current address on 24 September 2026 and the page did not render its content, so we are reporting Medsafe's citation of it rather than the entry itself.

Medsafe's own national reporting scheme had received ten reports associating finasteride with at least one of those symptoms at the time of writing, in people aged from 22 to 81, of whom three had recovered when the report was made.

What the drug's own label says

The US label does not use the phrase. What it does, in the post-approval section, is list "sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, libido disorders, ejaculation disorders, and orgasm disorders", along with male infertility and poor semen quality, and, under nervous system and psychiatric effects, depression and suicidal ideation and behaviour.

That section carries its own health warning, which matters in both directions: the reports come from a population of uncertain size, so frequency cannot be reliably estimated and causation cannot be established. It is not proof. It is also not nothing — and anyone telling you that persistent effects are an invention of internet forums is contradicting the approved labelling of the medicine.

What the UK found

On 29 April 2024 the MHRA published a safety update whose title contains the point in full: psychiatric side effects, and sexual side effects which may persist after discontinuation of treatment. It had received 426 Yellow Card reports of finasteride and sexual dysfunction since the first in November 1992 — and in almost half of them the outcome was recorded as not recovered or not resolved. Separately it had 281 reports of depressed mood disorders and suicidal or self-injurious behaviour.

The agency's explanation of why it acted is worth quoting in substance: the product information already contained this information, but the effects were not well known by prescribers and patients. So a patient card went into every pack. The problem it was solving was not an absence of evidence; it was an absence of awareness.

What the EU review concluded

The European review was the largest exercise anyone has run on this question. The Pharmacovigilance Risk Assessment Committee looked at clinical-trial data, the EudraVigilance database, literature case reports and studies, and also took evidence directly from patients, relatives, clinicians and patient organisations. The coordination group endorsed its measures on 19 June 2025 and the European Commission issued a binding decision on 22 August 2025.

Its findings, stated exactly: suicidal ideation is confirmed as a side effect of finasteride tablets; the frequency is unknown, meaning it cannot be estimated from available data; 325 relevant cases were identified, 313 for finasteride and 13 for dutasteride with one reported for both, against an estimated exposure of about 270 million patient-years for finasteride and about 82 million for dutasteride; most cases concerned patients treated for hair loss; and the benefits of the medicines continue to outweigh their risks for all approved uses.

Do not turn those numbers into a rate. Spontaneous reports are under-reported by an unknown factor and the exposure figure is an estimate, so dividing one by the other produces a number with no meaning. The EMA declined to state a frequency, which should tell you how solid the ground is.

The most honest sentence anyone has written about this

It belongs to the UK's expert advisory group, reported in the MHRA's update of 11 May 2026: the Yellow Card data came mainly from patients treated for hair loss, and the literature data showed mixed outcomes.

Mixed outcomes is what a contested evidence base looks like when someone is obliged to describe it accurately rather than persuasively.

The same update added a specific idea to the product information that is easy to read as dismissal and is not: sexual dysfunction may contribute to mood disorders, and sexual dysfunction has also been reported without mood alterations. The second half is the important half. The regulator is saying that both routes to low mood appear in the reports, not that the distress is merely secondary.

The three things nobody can tell you

• How often it happens. No regulator has published an incidence for persistent sexual dysfunction, and the EMA explicitly calls the frequency of suicidal ideation unknown. Any precise percentage you are quoted comes from somewhere other than a regulator.
• Who is at risk. No predictive test, genetic marker or risk factor has been established in the documents on this page.
• Whether it can be treated. Medsafe's 2016 article says plainly that there is no known cure and few, if any, effective treatments — and that article is now old enough that Medsafe itself flags its age. Nothing published since by the other three regulators contradicts it.

If you think this has happened to you

This site cannot examine you and does not know your history, so what follows is only the published route, in the order the regulators set it out. If depression or suicidal thoughts are involved, the MHRA's advice on the hair-loss tablet is to stop it and contact a doctor as soon as possible. If you have harmed yourself or feel at risk of serious harm, call your local emergency number now — 999 in the UK, 911 in the US, 112 across the EU.

1. See a doctor and take a timeline with you: when you started, what changed, when you stopped, what has and has not recovered.
2. Report it. In the UK that is the Yellow Card scheme; in the US, MedWatch. Every figure quoted on this page exists because people filed reports, including the ones that persuaded two regulators to change a label.
3. Ask your prescriber what else could explain the symptoms, and insist that the question is investigated rather than settled in one appointment.

For the underlying medicine — what it is licensed for, and the trial figures the licence rests on — see finasteride, from its licence to its warnings. For the documents on this page in the order they were written, with what each one changed, read the regulator record.